Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03635723 Recruiting - Breast Cancer Clinical Trials

Breast: Recovery After Axillary Node Clearance - Evaluating Limbs With E-Technology (the BRACELET Study)

BRACELET
Start date: April 23, 2018
Phase:
Study type: Observational

This work aims to use wearable sensors to record the return towards normal physical activity after breast surgery. It will build on current evidence by using objective measures of activity and arm movements rather than patient reports.

NCT ID: NCT03634501 Recruiting - Breast Cancer Clinical Trials

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells

Start date: August 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will analyze and evaluate the following items: 1. The safety of natural killer(NK) cells for treatment of subjects with solid tumors. Forty patients will be enrolled for each of the five cancers (in total 200 patients will be enrolled). 2. The effectiveness of natural killer(NK)cell therapy alone or with chemotherapy or targeted drugs. Subjects from 18 to 75 years of age who are diagnosed with a solid tumor including pancreatic cancer, lung cancer, breast cancer, ovarian cancer and colon cancer, and for whom standard treatments are not effective, may be eligible for this study. Participants undergo the following procedures: Peripheral blood will be collected from a vein of arm. Peripheral blood mononuclear cells(PBMC) will be isolated and purified for NK manufacturing. After 14~21 days cultivation, activated NK will be harvested and formulated for clinical administration. Subjects will receive NK cell treatment by intravenous infusion. The frequency is once per month for the first 3 treatment cycles. Participants who respond well after 3 treatment cycles may be eligible to continue NK cell therapy, and those not may receive NK therapy combined with chemotherapy and/or targeted drugs. Evaluations during therapy including: 1. Clinical assessment, and history of medications; 2. Blood draws for routine and research tests, including but not limited to: lymphocyte population and circulating tumor cell analysis in peripheral blood; 3. CT scan, bone scan and positron emission tomography(PET )scan, if indicated, for disease evaluation; 4. Pharmacokinetics study after NK infusion. For this test, the number of NK cells in the blood is measured over time at indicated time-points.

NCT ID: NCT03629756 Recruiting - Breast Cancer Clinical Trials

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Start date: July 24, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.

NCT ID: NCT03628677 Recruiting - Breast Cancer Clinical Trials

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Start date: August 7, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies.

NCT ID: NCT03626220 Recruiting - Breast Cancer Clinical Trials

Evaluation of the Efficacy of Acupuncture in Chemotherapy Induced Peripheral Neuropathy

Start date: June 27, 2018
Phase:
Study type: Observational

Peripheral neuropathy is currently the second most common side effect after chemotherapy, second only to the side effects of blood toxicity. A variety of chemotherapy drugs may induce peripheral neurotoxicity, and cause by the cumulative dose of chemotherapy drugs. Symptoms include sensory parasthesia, feeling dull or numbness, glove-like feeling distributed in the palm. The currently most effective way is to interrupt the treatment or adjust the dose of chemotherapeutic drugs, but it is easy to make patients discontinue chemotherapy. The purpose of this study is to explore the impact of acupuncture on neurological symptoms and quality of life. Three kinds of questionnairs will be used:(1) Brief pain inventory- short form to assess the extent of pain, and the impact of daily life. (2) FACT/GOG-NTX-13 (Version 4) to assess changes in neurological symptoms; (3) WHOQOL-BREF to assess changes in the quality of life of patients. The course of treatment was evaluated for nine weeks. Changes in neurological function and quality of life will be evaluated before treatment, the third week of treatment, the sixth week of treatment, till the ninth week. The aim of this study is to confirm that acupuncture can improve peripheral neuropathy after chemotherapy, in order to enhance breast cancer patients' quality of life, and provide the new opportunity for integrative therapy between Chinese and Western medicine. Keywords:acupuncture , chemotherapy-induced peripheral neuropathy

NCT ID: NCT03623945 Recruiting - Breast Cancer Clinical Trials

Autoantibodies in Breast Cancer Detection

ABCD
Start date: July 24, 2018
Phase:
Study type: Observational [Patient Registry]

Prospective, single-center study in women who have recently had an abnormal mammogram followed by a breast biopsy or women who have recently had a normal screening mammogram

NCT ID: NCT03623490 Recruiting - Breast Cancer Clinical Trials

Optimizing the Management of Patients With Oral Therapy

IPAC
Start date: May 22, 2018
Phase: N/A
Study type: Interventional

Oral anticancer treatments account a quarter of cancer treatments. These oral treatments are allowed at home, avoid hospitalization and limit the use of central venous routes. Oral treatments cause many side effects and patients are reluctant to report them because they are afraid that their treatment will be changed. But when these side effects are poorly managed, they can reduce adherence to treatment. The main hypothesis of this randomized study is that the combination of an initial consultation with a trio (nurse, doctor, pharmacist) and a weekly telephone nurse follow-up during the administration of oral anticancer treatments decreases the rate and duration of side effects. The main objective is to evaluate the impact at 3 months of a optimized management by an initial consultation with a trio nurse, doctor, pharmacist and a weekly nurse telephone follow-up versus a standard management on the level of digestive, skin and mucosal side effects of grade 3 in patients with oral chemotherapy. This randomized study is realized in patients with kidney or breast cancer.

NCT ID: NCT03619993 Recruiting - Breast Cancer Clinical Trials

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

CONVENIENCE
Start date: June 25, 2018
Phase: N/A
Study type: Interventional

The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics. Chemotherapy will be supported with pegfilgrastim for four subsequent chemotherapy cycles using alternating application forms.

NCT ID: NCT03619967 Recruiting - Breast Cancer Clinical Trials

Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers

Start date: July 20, 2018
Phase: N/A
Study type: Interventional

Surgery is the primary curative option for patients with cancer, with the overall objective of complete resection of all cancerous tissue while avoiding damage to healthy tissue. In addition, sentinel lymph node (SLN) mapping and resection is an essential step in staging and managing the disease. Even with the latest advancements in imaging technology, incomplete tumor resection in patients with breast cancer is at an alarming rate of 20-25%, with recurrence rates of up to 27%. The clinical need for imaging instruments that provide real-time feedback in the operating room is unmet, largely due to the use of imaging systems based on contemporary technological advances in the semiconductor and optical fields, which have bulky and costly designs with suboptimal sensitivity and co-registration accuracy between multimodal images. To address these challenges, the investigators have introduced an innovative design comprising a bio-inspired multispectral sensor which can significantly improve image-guided surgery. The objective of this clinical study is to determine the feasibility of using a bio-inspired multispectral imaging system to detect sentinel lymph nodes and cancerous tissue during intraoperative procedures in patients with breast cancer.

NCT ID: NCT03619083 Recruiting - Breast Cancer Clinical Trials

Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer

Start date: July 13, 2018
Phase:
Study type: Observational

This study is being done to find out if a new series of evaluations called the SAE (Sensory-Attention-Executive) Battery can help researchers learn more about how cancer treatment does or does not change the way the brain processes/filters information, emotions, attention span, and behavior by comparing the results of the SAE Battery with traditional evaluations like questionnaires.